Ajinomoto Bio-Pharma Services
11040 Roselle Street
About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates.
Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs.
Learn more: www.AjiBio-Pharma.com
61 articles with Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that GeneDesign, Inc. has joined the global organization.
Jean-Baptiste Agnus Joins Ajinomoto Bio-Pharma Services' Global Leadership Team as Vice President of Sales and Marketing
Ajinomoto Bio-Pharma Services, a leading global provider of bio-pharmaceutical contract development and manufacturing services, is pleased to announce that Jean-Baptiste Agnus has joined Aji Bio-Pharma as Vice President of Sales and Marketing.
Ajinomoto Bio-Pharma Services, a leading global provider of bio-pharmaceutical contract development and manufacturing provided an update on several of its capital projects currently underway in both the United States and Belgium.
Ajinomoto and XL-protein Forge Strategic Alliance to Develop PASylated Therapeutics Applying the Corynex® Platform
Ajinomoto Bio-Pharma Services and XL-protein GmbH, are pleased to announce a Strategic Alliance.
Ajinomoto Bio-Pharma Services presented data at the World ADC Summit in San Diego this month describing a proprietary site-selective bioconjugation technology, AJICAP™.
Ajinomoto Althea, Inc. celebrated its 20th year in operation, making it one of the true anchors of the San Diego life science community.
Ajinomoto Althea, Inc. announced that Bert Barbosa and Darwin Richardson, MBA, have joined Althea as Vice President of Drug Product Manufacturing and Vice President of Compliance, respectively.
Ajinomoto Althea Inc. Opens Manufacturing Suites In New High Potency And Antibody Drug Conjugate Commercial Facility
Biologics Candidate Manufactured Using Ajinomoto Althea Inc.'s CORYNEX Protein Expression System Enters Clinical Trials For The First Time
Ajinomoto Althea Inc. Announces Issuance Of New US Patent For Manufacturing Of Crystal Monoclonal Antibodies
Ajinomoto Althea Inc. Expands Its Capacity Of Fill Finish Manufacturing With Addition Of Second Shift
Ajinomoto Althea Inc. Launches Process And Analytical Development Services For Antibody Drug Conjugates (ADCs) Therapeutics
Ajinomoto Althea Inc. Receives European GMP Certification For Commercial Aseptic Filling And Testing
Althea Technologies, Inc. & Profectus BioSciences, Inc. Sign Manufacturing Agreement for Plasmid DNA Production
Pfenex Inc. Awards Althea Technologies, Inc. a Contract for cGMP Manufacturing of Circumsporozoite Protein From Plasmodium Falciparum, a Key Malaria Antigen